Detalhe da pesquisa
1.
Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.
Nature
; 554(7693): 554, 2018 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29342137
2.
mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.
Nature
; 547(7661): 109-113, 2017 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28658205
3.
Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
Br J Cancer
; 124(3): 552-563, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33106584
4.
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).
Br J Cancer
; 119(9): 1052-1059, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30131546
5.
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.
Cancers (Basel)
; 13(10)2021 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34066080
6.
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol
; 37(6): 490-503, 2019 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30625039